GlassScriptPhysician profile
Vivian Sona
NPI 1902358377
$2,839.19
in general payments reported to CMS, 2019-2025
19 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $396 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $405.52 | 2024-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $307.73 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $274.81 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.99 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $224.20 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $214.53 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $204.33 | 2024-2025 | Auvelity |
| Lundbeck LLC | $185.51 | 2024-2025 | Rexulti |
| Corium, LLC | $160.98 | 2024-2025 | Azstarys |
| Indivior INC. | $123.30 | 2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $102.97 | 2024-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $94.28 | 2024-2025 | Ingrezza |
| Braeburn INC. | $84.60 | 2025 | Brixadi |
| Tris Pharma INC | $60.95 | 2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $57.03 | 2024-2025 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $36.66 | 2024-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $33.94 | 2024 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $22.90 | 2025 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $17.96 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Sona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.